Search

Your search keyword '"Silverman, Earl"' showing total 477 results
Start Over Author "Silverman, Earl" Search Limiters Full Text
477 results on '"Silverman, Earl"'

1. Outcome of Antibody‐Mediated Fetal Heart Disease With Standardized Anti‐Inflammatory Transplacental Treatment

Author

Mawad, Wadi, Hornberger, Lisa, Cuneo, Bettina, Raboisson, Marie‐Josée, Moon‐Grady, Anita J, Lougheed, Jane, Diab, Karim, Parkman, Julia, Silverman, Earl, and Jaeggi, Edgar

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Pediatric, Cardiovascular, Heart Disease, Prevention, Reproductive health and childbirth, Good Health and Well Being, Anti-Inflammatory Agents, Antibodies, Atrioventricular Block, Child, Child, Preschool, Dexamethasone, Endocardial Fibroelastosis, Female, Fetal Diseases, Humans, Immunoglobulins, Intravenous, Infant, Newborn, Pregnancy, cardiomyopathy, fetal, heart block, outcome, steroids, treatment, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

Background Transplacental fetal treatment of immune-mediated fetal heart disease, including third-degree atrioventricular block (AVB III) and endocardial fibroelastosis, is controversial. Methods and Results To study the impact of routine transplacental fetal treatment, we reviewed 130 consecutive cases, including 108 with AVB III and 22 with other diagnoses (first-degree/second-degree atrioventricular block [n=10]; isolated endocardial fibroelastosis [n=9]; atrial bradycardia [n=3]). Dexamethasone was started at a median of 22.4 gestational weeks. Additional treatment for AVB III included the use of a β-agonist (n=47) and intravenous immune globulin (n=34). Fetal, neonatal, and 1-year survival rates with AVB III were 95%, 93%, and 89%, respectively. Variables present at diagnosis that were associated with perinatal death included an atrial rate

Published
2022

2. Evaluation of Progression From Preclinical to Systemic Autoimmune Rheumatic Disease: Novel Use of the European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria as an Outcome Measure

Author

Johnson, Sindhu R., Alahmari, Hana, Bonilla, Dennisse, Ahmad, Zareen, Bookman, Arthur, Hiraki, Linda T., Silverman, Earl, Touma, Zahi, Movahedi, Mohammad, and Wither, Joan E.

Subjects
NEPHRITIS, RHEUMATOID arthritis, SYSTEMIC lupus erythematosus, FLUORESCENT antibody technique, DESCRIPTIVE statistics, LONGITUDINAL method, AUTOIMMUNE diseases, SYSTEMIC scleroderma, DELIRIUM, SJOGREN'S syndrome, CONFIDENCE intervals, DISEASE progression, SENSITIVITY & specificity (Statistics)
Abstract

Objective: Our objective was to evaluate the development of a systemic autoimmune rheumatic disease (SARD) in undifferentiated and asymptomatic individuals with antinuclear antibodies (ANAs). We comparatively evaluated those who did and did not develop a SARD and fulfillment of classification criteria. Methods: We conducted a cohort study of undifferentiated and asymptomatic patients with ANAs who were assessed for the development of a SARD. The primary outcome was a diagnosis of a SARD over a two‐year period. We assessed fulfillment of classification criteria. Risk ratios (RRs) were used to evaluate differences among those who did and did not progress to a SARD. Results: We evaluated 207 asymptomatic ANA‐positive or undifferentiated patients, of whom 23 (11%) progressed to a SARD, whereas 187 (89%) did not progress. Progressors developed systemic lupus erythematosus (SLE) (n = 11 [48%]), Sjögren disease (n = 5 [22%]), systemic sclerosis (n = 3 [13%]), rheumatoid arthritis (n = 1 [4%]), and from ANA‐positive to undifferentiated connective tissue disease (n = 3 [13%]). Fever (RR 0.89, 95% confidence interval [CI] 0.8–0.93) and antiphospholipid antibodies (RR 0.89, 95% CI 0.87–0.93) occurred less frequently, whereas arthritis (RR 1.74, 95% CI 1.20–2.55) occurred more frequently in progressors. Progressors to SLE had arthritis (91%), whereas none developed delirium, psychosis, or nephritis. Among patients with SLE, 100% fulfilled the EULAR/American College of Rheumatology (ACR) SLE criteria (sensitivity 91.7%, specificity 100%), whereas 73% fulfilled the 1997 ACR SLE criteria (sensitivity 81.8%, specificity 98.9%). Conclusion: Most undifferentiated/asymptomatic individuals with ANA do not progress to a SARD over a two‐year period. SLE progressors appear to have mild disease in the short term. The EULAR/ACR SLE criteria have improved ability to identify those who develop SLE. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test

Author

Lionel, Anath C., Costain, Gregory, Monfared, Nasim, Walker, Susan, Reuter, Miriam S., Hosseini, S. Mohsen, Thiruvahindrapuram, Bhooma, Merico, Daniele, Jobling, Rebekah, Nalpathamkalam, Thomas, Pellecchia, Giovanna, Sung, Wilson W.L., Wang, Zhuozhi, Bikangaga, Peter, Boelman, Cyrus, Carter, Melissa T., Cordeiro, Dawn, Cytrynbaum, Cheryl, Dell, Sharon D., Dhir, Priya, Dowling, James J., Heon, Elise, Hewson, Stacy, Hiraki, Linda, Inbar-Feigenberg, Michal, Klatt, Regan, Kronick, Jonathan, Laxer, Ronald M., Licht, Christoph, MacDonald, Heather, Mercimek-Andrews, Saadet, Mendoza-Londono, Roberto, Piscione, Tino, Schneider, Rayfel, Schulze, Andreas, Silverman, Earl, Siriwardena, Komudi, Snead, O. Carter, Sondheimer, Neal, Sutherland, Joanne, Vincent, Ajoy, Wasserman, Jonathan D., Weksberg, Rosanna, Shuman, Cheryl, Carew, Chris, Szego, Michael J., Hayeems, Robin Z., Basran, Raveen, Stavropoulos, Dimitri J., Ray, Peter N., Bowdin, Sarah, Meyn, M. Stephen, Cohn, Ronald D., Scherer, Stephen W., and Marshall, Christian R.

Published
2018
Full Text
View/download PDF

4. Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein

Author

Ardoin, Stacy P, Schanberg, Laura Eve, Sandborg, Christy I, Barnhart, Huiman X, Evans, Greg W, Yow, Eric, Mieszkalski, Kelly L, Ilowite, Norman T, Eberhard, Anne, Imundo, Lisa F, Kimura, Yuki, Levy, Deborah, von Scheven, Emily, Silverman, Earl, Bowyer, Suzanne L, Punaro, L, Singer, Nora G, Sherry, David D, McCurdy, Deborah K, Klein-Gitelman, Marissa, Wallace, Carol, Silver, Richard M, Wagner-Weiner, Linda, Higgins, Gloria C, Brunner, Hermine I, Jung, Lawrence, Soep, Jennifer B, Reed, Ann M, Thompson, Susan D, and investigators, for the APPLE

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Autoimmune Disease, Clinical Research, Atherosclerosis, Clinical Trials and Supportive Activities, Lupus, Cardiovascular, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adolescent, Age Factors, Atorvastatin, Biomarkers, C-Reactive Protein, Carotid Arteries, Carotid Intima-Media Thickness, Cholesterol, LDL, Disease Progression, Double-Blind Method, Female, Heptanoic Acids, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Lupus Erythematosus, Systemic, Male, Prospective Studies, Puberty, Pyrroles, Treatment Outcome, Systemic Lupus Erythematosus, Autoimmune Diseases, APPLE investigators, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

ObjectiveParticipants in the Atherosclerosis Prevention in Paediatric Lupus Erythematosus (APPLE) trial were randomised to placebo or atorvastatin for 36 months. The primary endpoint, reduced carotid intima medial thickness (CIMT) progression, was not met but atorvastatin-treated participants showed a trend of slower CIMT progression. Post-hoc analyses were performed to assess subgroup benefit from atorvastatin therapy.MethodsSubgroups were prespecified and defined by age (> or ≤15.5 years), systemic lupus erythematosus (SLE) duration (> or ≤24 months), pubertal status (Tanner score≥4 as post-pubertal or

Published
2014

5. Cancer risk in childhood-onset systemic lupus

Author

Bernatsky, Sasha, Clarke, Ann E, Labrecque, Jeremy, von Scheven, Emily, Schanberg, Laura E, Silverman, Earl D, Brunner, Hermine I, Haines, Kathleen A, Cron, Randy Q, O’Neil, Kathleen M, Oen, Kiem, Rosenberg, Alan M, Duffy, Ciarán M, Joseph, Lawrence, Lee, Jennifer L, Kale, Mruganka, Turnbull, Elizabeth M, and Ramsey-Goldman, Rosalind

Abstract

Abstract Introduction The aim of this study was to assess cancer incidence in childhood-onset systemic lupus erythematosus (SLE). Methods We ascertained cancers within SLE registries at 10 pediatric centers. Subjects were linked to cancer registries for the observational interval, spanning 1974 to 2009. The ratio of observed to expected cancers represents the standardized incidence ratio (SIR) or relative cancer risk in childhood-onset SLE, versus the general population. Results There were 1020 patients aged

Published
2013

6. Cancer risk in childhood-onset systemic lupus.

Author

Schanberg, Laura, Silverman, Earl, Brunner, Hermine, Haines, Kathleen, Cron, Randy, ONeil, Kathleen, Oen, Kiem, Rosenberg, Alan, Duffy, Ciarán, Joseph, Lawrence, Lee, Jennifer, Kale, Mruganka, Turnbull, Elizabeth, Ramsey-Goldman, Rosalind, Bernatsky, Sasha, Clarke, Ann, Labrecque, Jeremy, and Von Scheven, Emily

Subjects
Adolescent, Age of Onset, Child, Female, Humans, Incidence, Lupus Erythematosus, Systemic, Male, Neoplasms, Registries, Risk Factors
Abstract

INTRODUCTION: The aim of this study was to assess cancer incidence in childhood-onset systemic lupus erythematosus (SLE). METHODS: We ascertained cancers within SLE registries at 10 pediatric centers. Subjects were linked to cancer registries for the observational interval, spanning 1974 to 2009. The ratio of observed to expected cancers represents the standardized incidence ratio (SIR) or relative cancer risk in childhood-onset SLE, versus the general population. RESULTS: There were 1020 patients aged

Published
2013

7. A decade of progress in juvenile idiopathic arthritis treatments and outcomes in Canada: results from ReACCh-Out and the CAPRI registry

Author

Nguyen, Kelly, primary, Barsalou, Julie, additional, Basodan, Daniah, additional, Batthish, Michelle, additional, Benseler, Susanne M, additional, Berard, Roberta A, additional, Blanchette, Nicholas, additional, Boire, Gilles, additional, Bolaria, Roxana, additional, Bruns, Alessandra, additional, Cabral, David A, additional, Cameron, Bonnie, additional, Campillo, Sarah, additional, Cellucci, Tania, additional, Chan, Mercedes, additional, Chédeville, Gaëlle, additional, Chetaille, Anne-Laure, additional, Chhabra, Amieleena, additional, Couture, Julie, additional, Dancey, Paul, additional, De Bruycker, Jean-Jacques, additional, Demirkaya, Erkan, additional, Dhalla, Muhammed, additional, Duffy, Ciarán M, additional, Feldman, Brian M, additional, Feldman, Debbie E, additional, Gerschman, Tommy, additional, Haddad, Elie, additional, Heale, Liane, additional, Herrington, Julie, additional, Houghton, Kristin, additional, Huber, Adam M, additional, Human, Andrea, additional, Johnson, Nicole, additional, Jurencak, Roman, additional, Lang, Bianca, additional, Larché, Maggie, additional, Laxer, Ronald M, additional, LeBlanc, Claire M, additional, Lee, Jennifer J Y, additional, Levy, Deborah M, additional, Lim, Lillian, additional, Lim, Lily S H, additional, Luca, Nadia, additional, McGrath, Tara, additional, McMillan, Tamara, additional, Miettunen, Paivi M, additional, Morishita, Kimberly A, additional, Ng, Hon Yan, additional, Oen, Kiem, additional, Park, Jonathan, additional, Petty, Ross E, additional, Proulx-Gauthier, Jean-Philippe, additional, Ramsey, Suzanne, additional, Roth, Johannes, additional, Rosenberg, Alan M, additional, Rozenblyum, Evelyn, additional, Rumsey, Dax G, additional, Schmeling, Heinrike, additional, Schneider, Rayfel, additional, Scuccimarri, Rosie, additional, Shiff, Natalie J, additional, Silverman, Earl, additional, Soon, Gordon, additional, Spiegel, Lynn, additional, Stringer, Elizabeth, additional, Tam, Herman, additional, Tse, Shirley M, additional, Tucker, Lori B, additional, Turvey, Stuart, additional, Twilt, Marinka, additional, Duffy, Karen Watanabe, additional, Yeung, Rae S M, additional, and Guzman, Jaime, additional

Published
2023
Full Text
View/download PDF

9. Genetics of longitudinal kidney function in children and adults with systemic lupus erythematosus

Author

Tang, Thai-Son, primary, Liao, Fangming, additional, Webber, Declan, additional, Gold, Nicholas, additional, Cao, Jingjing, additional, Dominguez, Daniela, additional, Gladman, Dafna, additional, Knight, Andrea, additional, Levy, Deborah M, additional, Ng, Lawrence, additional, Paterson, Andrew D, additional, Touma, Zahi, additional, Urowitz, Murray B, additional, Wither, Joan, additional, Silverman, Earl D, additional, Pullenayegum, Eleanor M, additional, and Hiraki, Linda T, additional

Published
2023
Full Text
View/download PDF

11. Genetics of osteonecrosis in children and adults with systemic lupus erythematosus

Author

Webber, Declan, primary, Cao, Jingjing, additional, Dominguez, Daniela, additional, Gladman, Dafna D, additional, Knight, Andrea, additional, Levy, Deborah M, additional, Liao, Fangming, additional, Ng, Lawrence, additional, Paterson, Andrew D, additional, Touma, Zahi, additional, Wither, Joan, additional, Urowitz, Murray, additional, Silverman, Earl D, additional, and Hiraki, Linda T, additional

Published
2023
Full Text
View/download PDF

12. High-sensitivity cardiac troponin T in infants exposed to anti-Ro antibodies.

Author

Barsalou, Julie, Jaeggi, Edgar, Grosse-Wortmann, Lars, Laskin, Carl A, Adeli, Khosrow, and Silverman, Earl D

Subjects
TROPONIN, AUTOANTIBODIES, MATERNAL exposure, BIOMARKERS, CARDIOMYOPATHIES, INFLAMMATION, MAGNETIC resonance imaging, RETROSPECTIVE studies, PRENATAL exposure delayed effects, DESCRIPTIVE statistics, SYSTEMIC lupus erythematosus, CHILDREN
Abstract

Objectives Cardiac involvement in neonatal lupus erythematosis (NLE) can present as myocarditis/endocardial fibroelastosis (EFE). It is unknown whether high-sensitivity cardiac troponin T (hs-cTnT) is useful in identifying subclinical myocardial inflammation in infants exposed prenatally to anti-Ro antibodies. This study reports hs-cTnT levels in infants exposed to anti-Ro antibodies with/without cardiac NLE and reports cardiac MRI (CMR) findings in a subset of these children. Methods The study included 45 consecutive infants exposed prenatally to anti-Ro antibodies with (n  = 7) or without (n  = 38) cardiac NLE, who were seen at the SickKids NLE Clinic between 2012 and 2014. Hs-cTnT levels were measured at least once, and those infants with values of ≥30 ng/l were offered the opportunity to undergo CMR. Descriptive statistics were performed. Results Of 38 infants without cardiac NLE, 25 had a hs-cTnT level of ≥30 ng/l (including 1 of >113 ng/l); of these, 8 underwent CMR (all without myocarditis/EFE). All 7 infants with cardiac NLE had at least one hs-cTnT level of ≥30 ng/l, but only 2/7 had a level of >113 ng/l; 4/7 infants with cardiac NLE had CMR (all without myocarditis/EFE); 6/7 infants with cardiac NLE had their steroid treatment adjusted based on the trend in their hs-cTnT levels. Conclusion Only 3/45 anti-Ro antibodies–exposed infants had hs-cTnT values outside the reference range reported in healthy infants. None of 12 infants who had CMR had subclinical myocarditis/EFE. Routine measurement of hs-cTnT in every anti-Ro antibody–exposed infant is not indicated. Further studies are needed to define the role of hs-cTnT as a biomarker for cardiac NLE. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Maternal Anti‐Ro Antibody Titers Obtained With Commercially Available Immunoassays Are Strongly Associated With Immune‐Mediated Fetal Heart Disease.

Author

Jaeggi, Edgar, Kulasingam, Vathany, Chen, Jack, Fan, Chun‐Po Steve, Laskin, Carl, Hamilton, Robert M., Hiraki, Linda T., Silverman, Earl D., and Sepiashvili, Lusia

Subjects
FETAL heart abnormalities, AUTOANTIBODIES, BIOMARKERS, ECHOCARDIOGRAPHY, CARDIOMYOPATHIES, CHEMILUMINESCENCE assay, PREGNANT women, CONGENITAL heart disease, MEDICAL screening, IMMUNOASSAY, FETAL diseases, HEART block, RISK assessment, DESCRIPTIVE statistics, SYSTEMIC lupus erythematosus, ODDS ratio, LONGITUDINAL method, DISEASE risk factors, SYMPTOMS, FETUS
Abstract

Objective: Anti‐Ro antibody–positive mothers are frequently referred for serial echocardiography due to the fetal risk of developing heart block and endocardial fibroelastosis. Little is known why only some and not all offspring develop these cardiac manifestations of neonatal lupus (CNL). This prospective study examined associations between anti‐Ro antibody titers and fetal CNL. Methods: Antibody‐positive mothers referred since 2018 for fetal echocardiography at risk of CNL (group 1; n = 240) or with CNL (group 2; n = 18) were included. Maternal antibody titers were measured with a chemiluminescent immunoassay (CIA). Additional testing on diluted serum samples was used to quantify anti–Ro 60 antibody titers above the analytical measuring range (AMR) of the standard CIA (≥1,375 chemiluminescent units [CU]). Results: Among 27 total mothers with a fetal diagnosis of CNL, all displayed anti–Ro 60 antibody titers that exceeded the AMR of the CIA at least 10‐fold. Of 122 mothers in group 1 who underwent additional anti–Ro 60 antibody testing, event rates of CNL (n = 9) were 0% (0 of 45) among mothers with anti–Ro 60 antibody titers from 1,375–10,000 CU, 5% (3 of 56) among mothers with titers from 10,000–50,000 CU, but 29% (6 of 21) among mothers with titers >50,000 CU (odds ratio 13.1, P = 0.0008). Of mothers in group 2 with a primary diagnosis of CNL, 0% (0 of 18 mothers) had anti–Ro 60 antibody titers <10,000 CU, 44% (8 of 18 mothers) had titers from 10,000–50,000 CU, and 56% (10 of 18 mothers) had titers >50,000 CU. Conclusion: CNL is associated with substantially higher anti‐Ro antibody titers than are obtained using a standard CIA. Enhancing the assay measuring range allows an improved specificity of identifying pregnancies at risk of CNL. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Lupus-associated causal mutation in neutrophil cytosolic factor 2 (NCF2) brings unique insights to the structure and function of NADPH oxidase

Author

Jacob, Chaim O., Eisenstein, Miriam, Dinauer, Mary C., Ming, Wenyu, Liu, Qiang, John, Sutha, Quismorio,, Francesco P., Reiff, Andreas, Myones, Barry L., Kaufman, Kenneth M., McCurdy, Deborah, Harley, John B., Silverman, Earl, Kimberly, Robert P., Vyse, Timothy J., Gaffney, Patrick M., Moser, Kathy L., Klein-Gitelman, Marisa, Wagner-Weiner, Linda, Langefeld, Carl D., Armstrong, Don L., and Zidovetzki, Raphael

Published
2012

19. Identification of IRAK1 as a Risk Gene with Critical Role in the Pathogenesis of Systemic Lupus Erythematosus

Author

Jacob, Chaim O., Zhu, Jiankun, Armstrong, Don L., Yan, Mei, Han, Jie, Zhou, Xin J., Thomas, James A., Reiff, Andreas, Myones, Barry L., Ojwang, Joshua O., Kaufman, Kenneth M., Klein-Gitelman, Marisa, McCurdy, Deborah, Wagner-Weiner, Linda, Silverman, Earl, Ziegler, Julie, Kelly, Jennifer A., Merrill, Joan T., Harley, John B., Ramsey-Goldman, Rosalind, Vila, Luis M., Bae, Sang-Cheol, Vyse, Timothy J., Gilkeson, Gary S., Gaffney, Patrick M., Moser, Kathy L., Langefeld, Carl D., Zidovetzki, Raphael, Mohan, Chandra, and Vitetta, Ellen S.

Published
2009
Full Text
View/download PDF

20. Characterization of recurrent thrombosis in pediatric antiphospholipid syndrome

Author

Avila, Maria Laura, primary, Amiri, Nour, additional, Zavareh, Zahra Tofighi, additional, Al‐Saoud, Sima Abu, additional, Sabapathy, Christine, additional, Vincelli, Jennifer, additional, Moharir, Mahendranath, additional, Silverman, Earl, additional, Williams, Suzan, additional, Brandão, Leonardo R., additional, and Levy, Deborah, additional

Published
2022
Full Text
View/download PDF

31. Efficacy and Safety of Tocilizumab in Patients with Polyarticular Juvenile Idiopathic Arthritis: Data From a Phase 3 Trial.: 1597

Author

Brunner, Hermine, Ruperto, Nicolino, Zuber, Zbigniew, Keane, Caroline, Harari, Olivier, Kenwright, Andrew, Cuttica, Ruben J., Keltsev, Vladimir, Xavier, Ricardo, Penades, Inmaculada Calvo, Nikishina, Irina, Rubio-Perez, Nadina, Alekseeva, Ekaterina, Chasnyk, Vyacheslav, Chavez, Jose, Horneff, Gerd, Opoka-Winiarska, Violetta, Quartier, Pierre, Silva, Clovis A., Silverman, Earl D., Spindler, Alberto, Lovell, D. J., Martini, Alberto, and De Benedetti, Fabrizio

Published
2012

34. Predictors of Early Inactive Disease in a Juvenile Idiopathic Arthritis Cohort: Results of a Canadian Multicenter, Prospective Inception Cohort Study

Author

OEN, KIEM, TUCKER, LORI, HUBER, ADAM M., MIETTUNEN, PAIVI, SCUCCIMARRI, ROSIE, CAMPILLO, SARAH, CABRAL, DAVID A., FELDMAN, BRIAN M., TSE, SHIRLEY, CHéDEVILLE, GAëLLE, SPIEGEL, LYNN, SCHNEIDER, RAYFEL, LANG, BIANCA, ELLSWORTH, JANET, RAMSEY, SUZANNE, DANCEY, PAUL, SILVERMAN, EARL, CHETAILLE, ANNE-LAURE, CAMERON, BONNIE, JOHNSON, NICOLE, DORVAL, JEAN, PETTY, ROSS E., DUFFY, KAREN WATANABE, BOIRE, GILLES, HADDAD, ELIE, HOUGHTON, KRISTIN, SAINT-CYR, CLAIRE, TURVEY, STUART E., BENSELER, SUSANNE, CHEANG, MARY, YEUNG, RAE S. M., and DUFFY, CIARáN M.

Published
2009
Full Text
View/download PDF

36. Premature atherosclerosis in pediatric systemic lupus erythematosus: Risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort

Author

Schanberg, Laura E., Sandborg, Christy, Barnhart, Huiman X., Ardoin, Stacy P., Yow, Eric, Evans, Gregory W., Mieszkalski, Kelly L., Ilowite, Norman T., Eberhard, Anne, Levy, Deborah M., Kimura, Yukiko, von Scheven, Emily, Silverman, Earl, Bowyer, Suzanne L., Punaro, Lynn, Singer, Nora G., Sherry, David D., McCurdy, Deborah, Klein-Gitelman, Marissa, Wallace, Carol, Silver, Richard, Wagner-Weiner, Linda, Higgins, Gloria C., Brunner, Hermine I., Jung, Lawrence, Soep, Jennifer B., and Reed, Ann

Published
2009
Full Text
View/download PDF

37. High-density genotyping of STAT4 reveals multiple haplotypic associations with systemic lupus erythematosus in different racial groups

Author

Namjou, Bahram, Sestak, Andrea L., Armstrong, Don L., Zidovetzki, Raphael, Kelly, Jennifer A., Jacob, Noam, Ciobanu, Voicu, Kaufman, Kenneth M., Ojwang, Joshua O., Ziegler, Julie, Quismorio, Francesco P., Jr., Reiff, Andreas, Myones, Barry L., Guthridge, Joel M., Nath, Swapan K., Bruner, Gail R., Mehrian-Shai, Ruth, Silverman, Earl, Klein-Gitelman, Marisa, McCurdy, Deborah, Wagner-Weiner, Linda, Nocton, James J., Putterman, Chaim, Bae, Sang-Cheol, Kim, Yun Jung, Petri, Michelle, Reveille, John D., Vyse, Timothy J., Gilkeson, Gary S., Kamen, Diane L., Alarcón-Riquelme, Marta E., Gaffney, Patrick M., Moser, Kathy L., Merrill, Joan T., Scofield, Hal R., James, Judith A., Langefeld, Carl D., Harley, John B., and Jacob, Chaim O.

Published
2009
Full Text
View/download PDF

38. Feasibility and Effectiveness of an Aerobic Exercise Program in Children With Fibromyalgia: Results of a Randomized Controlled Pilot Trial

Author

STEPHENS, SAMANTHA, FELDMAN, BRIAN M., BRADLEY, NICOLETTE, SCHNEIDERMAN, JANE, WRIGHT, VIRGINIA, SINGH-GREWAL, DAVINDER, LEFEBVRE, ARLETTE, BENSELER, SUSANNE M., CAMERON, BONNIE, LAXER, RONALD, OʼBRIEN, CHRISTINE, SCHNEIDER, RAYFEL, SILVERMAN, EARL, SPIEGEL, LYNN, STINSON, JENNIFER, TYRRELL, PASCAL N., WHITNEY, KRISTI, and TSE, SHIRLEY M. L.

Published
2008

43. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis

Author

Ruperto, Nicolino, Lovell, Daniel J., Cuttica, Ruben, Wilkinson, Nick, Woo, Patricia, Espada, Graciela, Wouters, Carine, Silverman, Earl D., Balogh, Zsolt, Henrickson, Michael, Apaz, Maria-Teresa, Baildam, Eileen, Fasth, Anders, Gerloni, Valeria, Lahdenne, Pekka, Prieur, Anne-Marie, Ravelli, Angelo, Saurenmann, Rotraud K., Gamir, Maria Luz, Wulffraat, Nico, Marodi, Laszlo, Petty, Ross E., Joos, Rik, Zulian, Francesco, McCurdy, Deborah, Myones, Barry L., Nagy, Kalman, Reuman, Peter, Szer, Ilona, Travers, Suzanne, Beutler, Anna, Keenan, Greg, Clark, Jason, Visvanathan, Sudha, Fasanmade, Adedigbo, Raychaudhuri, Aparna, Mendelsohn, Alan, Martini, Alberto, and Giannini, Edward H.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results